Expanding JAK Inhibitors to Novel Applications

Publication ID: 24-11857669_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Expanding JAK Inhibitors to Novel Applications,” Published Technical Disclosure No. 24-11857669_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857669_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,669.

Summary of the Inventive Concept

This inventive concept leverages the core technology of JAK inhibitors to address unmet needs in diverse industries, including aquaculture, livestock, plant health, human exercise performance, and environmental pollution control.

Background and Problem Solved

The original patent focused on treating diseases of the gastrointestinal tract with JAK inhibitors. However, the potential of JAK inhibitors extends beyond this scope. The new inventive concept addresses the limitations of the original patent by exploring novel applications and use cases for JAK inhibitors, thereby unlocking new opportunities for improving health, productivity, and environmental sustainability.

Detailed Description of the Inventive Concept

The new inventive concept involves the use of ingestible devices configured to detect specific targets (e.g., waterborne pathogens, stress in livestock, plant pathogens, muscle fatigue, or environmental pollutants) and release JAK inhibitors to mitigate their effects. This approach enables targeted and controlled delivery of JAK inhibitors, reducing systemic exposure and potential side effects. The ingestible devices can be designed for various formats, such as capsules, tablets, or implants, depending on the specific application and target species.

Novelty and Inventive Step

The new claims introduce a paradigm shift in the use of JAK inhibitors, moving beyond gastrointestinal tract diseases to address unmet needs in distinct industries. The inventive concept's novelty lies in the combination of ingestible devices and JAK inhibitors, which enables targeted delivery and opens up new avenues for improving health, productivity, and environmental sustainability.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different types of JAK inhibitors, varying release mechanisms, or incorporating additional therapeutic agents. Variations may also involve adapting the ingestible devices for specific species, such as companion animals or fish, or developing implantable devices for long-term release of JAK inhibitors.

Potential Commercial Applications and Market

The new inventive concept has significant commercial potential across multiple industries, including aquaculture, livestock, plant health, human exercise performance, and environmental pollution control. The market opportunities are vast, with potential applications in improving food production, reducing environmental pollutants, and enhancing human health and well-being.

CPC Classifications

SectionClassGroup
A A61 A61K9/0009
A A61 A61K9/0004
A A61 A61K9/0053
A A61 A61K31/519

Field of Art

Pharmaceutical drug delivery systems, with expertise in targeted drug release, JAK inhibitor formulations, and ingestible medical devices for controlled therapeutic interventions

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced training in pharmaceutical engineering, biotechnology, or biomedical engineering, possessing knowledge of drug delivery mechanisms, device design, and therapeutic targeting strategies

Obviousness Rationale

A PHOSITA would recognize that the source patent's core teachings of JAK inhibitor delivery can be readily extended to alternative therapeutic and monitoring applications by leveraging known ingestible device technologies. The fundamental principles of targeted drug release and localized therapeutic intervention demonstrated in the source patent provide a clear technological foundation for exploring novel application domains. The PTD's variations represent predictable engineering adaptations that would be obvious to a skilled practitioner seeking to expand the utility of JAK inhibitor delivery systems.

Obvious Combinations & Variations

Source Patent Element
Oral administration of JAK inhibitor with controlled plasma concentration
PTD Variation
Expanding JAK inhibitor delivery to aquaculture, livestock, and plant health applications
Obviousness Reasoning
Known drug delivery principles enable predictable translation of localized therapeutic strategies across biological systems, representing a straightforward design adaptation
Source Patent Element
Ingestible device for targeted GI tract drug delivery
PTD Variation
Incorporating pathogen detection and responsive JAK inhibitor release mechanisms
Obviousness Reasoning
Integrating sensing and responsive drug delivery is a well-established technique in biomedical engineering, representing an obvious technological progression
Source Patent Element
Method of reducing systemic drug exposure through localized delivery
PTD Variation
Applying JAK inhibitor delivery to stress mitigation and performance enhancement
Obviousness Reasoning
Extending targeted drug delivery to adjacent physiological domains is a predictable engineering approach with clear precedent in pharmaceutical research
Source Patent Element
Pharmaceutical composition with specific plasma concentration constraints
PTD Variation
Developing multi-species and cross-industry ingestible device platforms
Obviousness Reasoning
Modular device design and adaptable drug delivery principles enable straightforward technological translation across different biological contexts
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857669 and the published technical disclosure, a person having ordinary skill in the art would find the proposed variations in JAK inhibitor delivery and application domains to be obvious extensions of existing pharmaceutical engineering principles, thereby rendering potential claims to such technologies unpatentable under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,669
TitleTreatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
Assignee(s)Biora Therapeutics, Inc.